drugset
drugset / Trial / NCT07622186

A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT07622186 ↗

Phase 2 Not yet recruiting 150 enrolled Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).

Timeline

Start
2026-07-31
Primary completion
2028-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intravenous
Subject Cisplatin Other / unclassified — Intravenous
Subject Firmonertinib Small molecule — Oral
Subject Osimertinib Small molecule — Oral
Subject Pembrolizumab Monoclonal antibody — Intravenous
Subject SKB571 Unknown — Intravenous

Indications

non-small cell lung carcinoma